-
Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging
•
Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT firm Salus Optima to provide precision health solutions that promote healthy aging through data-driven lifestyle recommendations on mobile devices. This collaboration will leverage Bayer’s extensive global network to distribute Salus Optima’s AI-powered lifestyle analysis technology.…
-
MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III trial for its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with AstraZeneca’s (AZ; NASDAQ: AZN) co-developed PARP inhibitor Lynparza (olaparib) for metastatic squamous non-small cell lung cancer (NSCLC). The decision follows the trial’s failure to meet…
-
Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer
•
Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor Kisqali (ribociclib) in early breast cancer. Data from 78.3% of patients who completed treatment showed a significant reduction in the risk of recurrence, with 30% and 24.5% decreases for stage II and stage III tumors,…
-
Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District
•
Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event in Shenzhen the establishment of a Greater Bay Area (GBA) headquarters for Fosun Pharma (HKG: 2196, SHA: 600196) in the Pingshan district of Shenzhen. This new site will serve as Fosun Pharma’s second global headquarters,…
-
Keymed Biosciences’ Stapokibart Filing Accepted for Priority Review in China for Atopic Dermatitis
•
Keymed Biosciences Inc. (HKG: 2162) has announced that its market filing for stapokibart (CM310), a monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα), has been accepted for priority review by the National Medical Products Administration (NMPA) for the treatment of moderate to severe atopic dermatitis (AD). The filing is supported…
-
Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement with Grand Life Sciences Co., Ltd., aimed at advancing the commercialization of Zelgen’s recombinant human thrombin product in Greater China. Under the terms of the agreement, Grand Life will serve as the sole marketing promotion…
-
Pfizer and CStone Secure NMPA Approval for Sugemalimab, First PD-L1 Inhibitor for ESCC
•
Pfizer (NYSE: PFE) and CStone Pharmaceuticals (HKG: 2616) have secured market approval from the National Medical Products Administration (NMPA) for sugemalimab, a treatment for first-line irresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) in combination with fluorouracil and platinum. This approval marks sugemalimab as the first programmed…
-
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
•
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues…
